What is the prognosis of angioplasty (percutaneous coronary intervention) or coronary artery bypass grafting (CABG) for patients with a left ventricular ejection fraction of approximately 48%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prognosis of Revascularization in Patients with 48% Ejection Fraction

For patients with chronic coronary syndrome and an ejection fraction of 48%, both CABG and PCI can improve long-term survival and reduce cardiovascular mortality when functionally significant coronary disease is present, with CABG generally offering superior outcomes for multivessel disease, particularly in diabetic patients. 1

Understanding the Clinical Context

An ejection fraction of 48% places this patient in the mild-to-moderate left ventricular dysfunction category (LVEF 35-50%). This is a critical distinction because current guidelines stratify revascularization recommendations at the 35% threshold 1, 2.

Key Prognostic Factors

The prognosis depends heavily on:

  • Coronary anatomy complexity (left main, three-vessel, proximal LAD involvement)
  • Extent of functionally significant disease (not just anatomic stenosis)
  • Presence of viable myocardium in the territory to be revascularized
  • Diabetes status (significantly favors CABG outcomes)
  • Surgical risk profile (STS score, comorbidities)

Survival Benefits by Revascularization Strategy

CABG Outcomes

CABG demonstrates clear survival advantages in this EF range when specific anatomic criteria are met 1, 2:

  • Left main stenosis: Class I recommendation to improve survival (Level A evidence) 1
  • Three-vessel disease: Class I recommendation for long-term survival and reduced cardiovascular mortality (Level A evidence) 1
  • Proximal LAD with single/two-vessel disease: Class I recommendation to reduce cardiovascular mortality (Level B evidence) 1

The 2024 ESC guidelines specifically state that in patients with LVEF >35% and multivessel disease, CABG is recommended to improve long-term survival and reduce the risk of spontaneous myocardial infarction 1.

For patients with EF 35-50%, CABG is reasonable when viable myocardium is present in the region of intended revascularization 2, 3. Historical data from the Coronary Artery Surgery Study showed 80% survival at 10 years with CABG versus 59% with medical therapy in patients with angina and LVEF <50% 4.

PCI Outcomes

PCI outcomes are more nuanced in this population:

  • For left main disease with low-intermediate anatomic complexity (SYNTAX score <33), PCI is reasonable as an alternative to CABG in selected patients 1, 3
  • For multivessel disease, the survival benefit of PCI is uncertain (Class IIb, Level B) 2, 3
  • PCI is definitively indicated for symptom relief when medical therapy fails (Class I, Level A) 1

Comparative Data: CABG vs PCI

Recent high-quality research provides critical insights for this EF range:

The most compelling evidence comes from a 2020 Ontario population study 5 of 4,794 propensity-matched patients with LVEF <35%. While this studied more severe dysfunction, the findings are directionally relevant:

  • Mortality: PCI patients had 60% higher mortality (HR 1.6,95% CI 1.3-1.7)
  • Cardiovascular death: 40% higher with PCI (HR 1.4)
  • Major adverse cardiac events: Doubled with PCI (HR 2.0)
  • Repeat revascularization: Nearly 4-fold higher with PCI (HR 3.7)
  • Heart failure hospitalization: 50% higher with PCI (HR 1.5)

A 2021 University of Pittsburgh study 6 of patients with mean EF 35% showed:

  • 5-year freedom from MACCE: 74% with CABG vs 54.5% with PCI (p<0.001)
  • Overall mortality: 21.3% with CABG vs 37.4% with PCI (p<0.001)
  • CABG associated with 43% reduction in mortality risk (HR 0.57)

A 2017 meta-analysis 7 of 6,082 patients with LV systolic dysfunction demonstrated:

  • 18% lower long-term mortality with CABG (OR 0.82, p=0.01)
  • 42% reduction in myocardial infarction (OR 0.58, p=0.03)
  • 83% reduction in repeat revascularization (OR 0.17, p<0.001)

Specific Prognostic Considerations

For Multivessel Disease with Diabetes

CABG is strongly preferred over PCI in diabetic patients with multivessel disease, particularly when a left internal mammary artery graft can be used to the LAD 2, 3. This represents a Class IIa recommendation with Level B evidence.

For Complex Three-Vessel Disease

CABG is preferred over PCI when the SYNTAX score exceeds 22, indicating anatomic complexity 2, 8, 3. This is a Class IIa recommendation with Level B evidence.

Symptom Relief

Both CABG and PCI are equally effective for symptom improvement when guideline-directed medical therapy fails (Class I, Level A) 1, 9. However, PCI patients experience higher rates of repeat revascularization for recurrent symptoms.

Critical Pitfalls to Avoid

  1. Don't assume all stenoses need revascularization: Functional significance (FFR <0.80) should guide lesion selection, not just anatomic appearance 1

  2. Don't overlook viability assessment: While the STICH trial showed viability testing didn't predict outcomes in severe LV dysfunction, the presence of viable myocardium in the 35-50% EF range remains important for decision-making 10, 11

  3. Don't underestimate the importance of complete revascularization: Incomplete revascularization with PCI correlates with worse outcomes 11

  4. Don't ignore the Heart Team approach: For complex cases where both CABG and PCI are reasonable options, multidisciplinary discussion is mandated (Class I, Level C) 1

Practical Algorithm for Decision-Making

Step 1: Determine coronary anatomy complexity

  • Left main disease → CABG preferred (PCI reasonable if low SYNTAX score and high surgical risk)
  • Three-vessel disease → CABG preferred (especially if diabetic or SYNTAX >22)
  • Proximal LAD involvement → CABG reasonable with extensive ischemia

Step 2: Assess surgical candidacy

  • Calculate STS score for operative mortality risk 1
  • If prohibitive surgical risk → PCI may be considered

Step 3: Evaluate for viability

  • If viable myocardium present in target territory → Revascularization more likely beneficial

Step 4: Consider patient factors

  • Diabetes present → Strongly favor CABG
  • Patient preference after shared decision-making
  • Ability to tolerate dual antiplatelet therapy (for PCI)

Step 5: Symptom burden

  • Refractory angina despite medical therapy → Either modality appropriate (Class I)
  • Asymptomatic with anatomy meeting survival criteria → CABG preferred for multivessel disease

Expected Outcomes

For a patient with 48% EF undergoing appropriate revascularization:

With CABG:

  • 30-day mortality: approximately 3-5% 11
  • 5-year survival: approximately 75-80% 6, 5
  • Freedom from MACCE at 5 years: approximately 74% 6
  • Repeat revascularization: 2-7% 6, 5

With PCI:

  • 30-day mortality: approximately 5-6% 6
  • 5-year survival: approximately 55-65% 6, 5
  • Freedom from MACCE at 5 years: approximately 54% 6
  • Repeat revascularization: 6-11% 6, 5

These outcomes assume appropriate patient selection, complete revascularization, and guideline-directed medical therapy continuation post-procedure.

References

Related Questions

If a patient's left ventricular ejection fraction improves to 44%, can the wearable cardioverter‑defibrillator (LifeVest) be discontinued?
What is considered a normal left ventricular ejection fraction (LVEF)?
After how many months can left ventricular ejection fraction be expected to improve following initiation of immunosuppressive therapy?
What is the appropriate management for an 80-year-old asymptomatic male with a left ventricular ejection fraction of 45%?
A patient’s electrocardiogram (ECG) shows sinus rhythm without conduction abnormalities or premature complexes, and left ventricular ejection fraction (LVEF) is less than 40%. Can the patient be cleared for back surgery?
What should I do with an INR of 3.3 while alternating warfarin (warfarin) doses of 2.5 mg and 3 mg?
Which additional laboratory tests should be obtained for a patient with markedly elevated alanine aminotransferase (ALT) 1044 U/L, aspartate aminotransferase (AST) 443 U/L, mildly elevated alkaline phosphatase 198 U/L, bilirubin 3.3 mg/dL, and normal lipase 84 U/L?
For a typical adult, should iron tablets be taken with food or on an empty stomach to minimize constipation?
What medication regimen should be used to treat marked hyperglycemia and stop osmotic diuresis?
Can nitrofurantoin be used to treat an uncomplicated urinary tract infection in a 3-year-old child, and what is the appropriate dosing?
What is the appropriate topical treatment for facial contact dermatitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.